Email updates

Keep up to date with the latest news and content from BMC Neuroscience and BioMed Central.

This article is part of the supplement: Annual Meeting of the Study Group Neurochemistry. International Conference of the Gesellschaft für Biochemie und Molekularbiologie 2006 (GBM 2006): Molecular pathways in health and disease of the nervous system

Open Access Poster presentation

Identification of ADAM proteinase substrates in neurodegeneration and neuroinflammation

Silvia Naus*, Simone Reipschläger, Dirk Wildeboer, Yuji MInai, Stefan F Lichtenthaler, Stefan Mitterreiter, Ziqiang Guan, Marcia L Moss and Jörg W Bartsch

  • * Corresponding author: Silvia Naus

Author Affiliations

King's College, London, UK

For all author emails, please log on.

BMC Neuroscience 2007, 8(Suppl 1):P30  doi:10.1186/1471-2202-8-S1-P30

The electronic version of this article is the complete one and can be found online at:

Published:23 March 2007

© 2007 Naus et al; licensee BioMed Central Ltd.

Poster presentation

ADAM proteases are type I transmembrane proteins with extracellular metalloprotease domains. Like most ADAM family members, ADAM8 (CD156a, MS2) is involved in ectodomain shedding of membrane proteins and is linked to neuroinflammation and neurodegeneration. To identify potential substrates released under these pathologic conditions, we screened 10-mer peptides representing amino acid sequences from extracellular domains of various membrane proteins using the ProteaseSpot™ system. A soluble ADAM8 protease containing pro- and metalloprotease domain was expressed in E. coli and purified as active protease due to autocatalytic prodomain removal. From 34 peptides tested in the peptide cleavage assay, significant cleavage by soluble ADAM8 was observed for 14 peptides representing membrane proteins with functions in inflammation and neurodegeneration, among them the beta amyloid precursor protein (APP) and the Tumor Necrosis Factor alpha Receptor type I (TNFRI). The in vivo relevance of the ProteaseSpot™ method was confirmed by cleavage of full length APP with ADAM8 in human embryonic kidney 293 cells expressing tagged APP. ADAM8 cleaved APP with similar efficiency as ADAM10, whereas inactive ADAM8 mutant did not. Cleavage of TNFRI was assessed in primary cell lines deficient in ADAM8 and revealed a gene dosage-dependent effect. Exchanging amino acids at defined positions in the cleavage sequence of myelin basic protein (MBP) revealed sequence criteria for ADAM8 cleavage. Taken together, we identified novel substrates that could be cleaved by ADAM8 in vivo under pathologic conditions.